



GOVERNMENT OF PAKISTAN  
(CABINET DIVISION)  
INTELLECTUAL PROPERTY ORGANIZATION  
THE PATENT OFFICE  
**KARACHI**



To,

Dated: 10-7-2008

Mr. Yasin Tahir,  
Director General, IPO-Pakistan  
**Islamabad.**

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEKENDING 07-6-2008 TO BE PUBLISHED 11-7-2008 IN THE  
GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 9215488

**ENCL:**

**GOVERNMENT OF PAKISTAN  
THE PATENT OFFICE**

2nd Floor, Kandawala Building,  
M.A. Jinnah Road,  
Karachi

No.2/2/2003-F.Sec.

Dated: 10-7-2008

To,

Mr. Manzoor Ahmed  
Section Officer  
Cabinet Secretariat  
Cabinet Division  
Government of Pakistan  
Islamabad

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEKENDING 07-6-2008 TO BE PUBLISHED 11-7-2008 IN THE  
GAZETTE OF PAKISTAN PART-V.**

Reference to Cabinet Secretariats letter No. 18/IPO/2008/RA-IV, dated 23<sup>rd</sup> April 2008. A manuscript copy of the weekly notification regarding application filed, application accepted and sealing fee due etc., is enclosed herewith for onward transmission to the Printing Corporation of Pakistan Press for publication in the next issue of the Gazette of Pakistan Part-V.

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 9215488

ENCL:

## NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

612/2008	<b><u>02-6-2008</u></b> H. Dilawari, A. R. Saleemi, N. Ahmed, S. R. Lahore, Pakistan	“Conservation of natural gas with novel design modifications in locally made water batch heaters (geysers)”
613/2008	Bristol-Myers Squibb Company, U.S.A. (Priority 23-04-04 U.S.A) <b>DIVISIONAL</b>	“Pharmaceutically acceptable salt of monocyclic heterocycles as kinase inhibitors”
614/2008	Insigion Holdings Limited, Bermuda (Priority 01-6-07 GB)	“Plant extract and its therapeutic use”
615/2008	Nazeel, A. Qureshi Islamabad-Pakistan	“Solar wave trap”
616/2008	Nazeel, A. Qureshi Islamabad-Pakistan	“Undersea current power generator”
617/2008	F. L. Smidth A/S. Denmark (Priority 25-7-07 Denmark)	“Roller press with flexible annular disc sections”
618/2008	F. L. Smidth A/S. Denmark (Priority 10-7-07 Denmark)	“Roller press with adjustable plates”
619/2008	Bayer CropScience AG, Germany (Priority 06-6-07 Europe)	“Insecticidal compositions with improved action”
620/2008	Bayer CropScience AG, Germany (Priority 13-6-07 Europe)	“Heterocyclically substituted hererocyclylcarbocylic acid derivatives”
621/2008	Novartis AG, Switzerland (Priority 04-6-07 USA)	“Macrocycles and their uses”

622/2008	Novartis AG, Switzerland (Priority 04-6-07 USA)	“Organic compounds”
	<b><u>03-6-2008</u></b>	
623/2008	Media Work Table AG, Switzerland	“A deposition device for a bedside table for a hospital bed”
624/2008	Theravance, Inc. USA (Priority 05-6-07 USA)	“Dual-acting benzoimidazole antihypertensive agents”
625/2008	Sanofi-Aventis France (Priority 05-6-07 Europe)	“Di(hetro)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them”
626/2008	Sanofi-Aventis France (Priority 05-6-07 USA)	“Substituted benzoylamino-indan-2-carboxylic acids and related compounds”
627/2008	Bayer HealthCare Ag, Germany (Priority 03-9-04 Germany) <b>Divisional</b>	“A salt solvate and solvate of the salt of a substituted phenyl aminothiazole compounds”
628/2008	Bayer HealthCare Ag, Germany (Priority 20-7-07 Germany)	“Substituted oxazolidinones and their use”
629/2008	Schering Corporation USA (Priority 05-6-07 USA)	“Novel compounds that are erk inhibitors”
630/2008	Bayer HealthCare Ag, Germany (Priority 20-7-07 Germany)	“Substituted oxazolidinones and their use”
631/2008	Bayer HealthCare Ag, Germany (Priority 20-6-07 Germany)	“Substituted oxazolidinones and their use”
	<b><u>04-6-2008</u></b>	
632/2008	Domantis Limited, United Kingdom (Priority 06-6-07 USA)	“Polyperptides, antibody variable domains & antagonists”

633/2008	Domantis Limited, United Kingdom (Priority 06-6-07 USA)	“Polyperptides, antibody variable domains & antagonists”
634/2008	Domantis Limited, United Kingdo (Priority 06-6-07 USA)	“Polyperptides, antibody variable domains & antagonists”
635/2008	Domantis Limited, United Kingdom (Priority 06-6-07 USA)	“Polyperptides, antibody variable domains & antagonists”
636/2008	SmithKline Beecham Corporation, USA (Priority 06-6-07 USA)	“Chemical compounds”
637/2008	1.Boehringer Ingelheim International GmbH, Germany 2. Syntonix Pharmaceuticals, Inc. USA (Priority 06-6-07 USA)	“Natriuretic fusion proteins”
638/2008	SmarTech Design Pty Limited, Australia	“A foldable enclosure”
639/2008	F. Hoffmann La-Roche AG, Switzerland (Priority 10-5-2002 Europe) <b>Divisional</b>	“A pharmaceutical composition containing inandronate mono sodium salt mone hydrate”
640/2008	Merck Patent GmbH, Germany (Priority -6-6-07 Germany)	“S. specification”
641/2008	Janssen Pharmaceutica N. V. Belgium (Priority 06-6-07 USA)	“Spirobenzozepanes as vasopressin antagonists”
642/2008	Janssen Pharmaceutica N. V. Belgium (Priority 07-6-07 USA)	“ Urotensin II receptor antagonists ”

643/2008	Otsuka Pharmaceutical Co. Ltd., Japan (Priority 06-6-07 Japan)	“Quinolone compound and pharmaceutical composition”
644/2008	Takeda Pharmaceutical Company Limited, Japan (Priority 05-6-07 Japan)	“Fused heterocycle derivatives and use thereof”
	<b><u>05-6-2008</u></b>	
645/2008	Dolki Korea Ltd., Korea (Priority 21-8-07 Korea)	“Manufacturing method of medical sterilized normal saline having low-concentratedly controlled free chlorine including hypochlorous acid therein”
646/2008	AstraZeneca AB, Sweden (Priority 07-6-07 USA)	“Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators 841”
647/2008	AstraZeneca AB, Sweden (Priority 07-6-07 USA)	“Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators 842”
648/2008	Dr. S. Riazuddin & Dr. Tayyab Husnain Lahor, Pakistan	“Gene pyramiding and hbrid cotton production of Pakistani Cotton Varieties”
649/2008	Mian Mehmood Ahmad Lahore, Pakistan	“Water safe fc-30B (prevent formation of scale in A/C plants. Protect all undergrounds {upper system from solids”
650/2008	Mian Mehmood Ahmad Lahore, Pakistan	“Water safe fc-120Q (anti scale & corrosion inhibitors or AC plants”
	<b><u>06-6-2008</u></b>	
651/2008	Dollar Industries, Pakistan Karachi, Pakistan	“An improved marker pen with easy ink re-filling arrangement”
652/2008	Mr. Muhammad Ishaque Shaikh P. C. S. I. R, Karachi, Pakistan	“”An improved pedestal fan”

653/2008	Mr. Liaquat Ali P. C. S. I. R, Karachi, Pakistan	“Water Pulling System”
654/2008	Janssen Pharmaceutica NV., Belgium (Priority 08-6-07 Europe)	“Piperidine/piperazine derivatives”
655/2008	Janssen Pharmaceutica NV., Belgium (Priority 08-6-07 Europe)	“Piperidine/piperazine derivatives”
656/2008	Boehringer Ingelheim International GmbH, Germany (Priority 08-6-07 USA)	“Extended release formulation of nevirxpine”
657/2008	Staubli Faverges France (Priority 08-6-07 France)	“Braking device, heald frame with such a braking device and loom with such a frame”
658/2008	IRM LLC, Bermuda (Priority 08-6-07 USA)	“Methods and compositions for inducing apoptosis in cancer cells”
659/2008	Sanofi-aventis France (Priority 07-6-07 Hungarian)	“New compounds”
660/2008	<b><u>07-6-2008</u></b> Novartis AG, Switzerland (Priority 08-6-07 Europe)	“Quinoxaline derivatives as tyrosine kinase activity inhibitors”
661/2008	Eisai R and D Management Co., Ltd. Japan (Priority 24-11-05 Japan) <b>Divisional</b>	“A slat of morpholine type cannamide compounds”
662/2008	Aventis Pharma S.A., France (Priority 08-6-07 France)	“Direct dissolution of docetaxel in a solvent in polysorbate 80”





chlorophenyl)-4, 5, 6, 7-tetrahydrothieno[3,2-c]pyridine-5-acetate.


710/1999 Sumitomo  
Chemical  
Company, Ltd.  
Japan.

“A pesticidal composition containing 3,5-dichloro-1-(3,3-dichloro-2-propenyloxy)-4-[3-(5-trifluoromethylpyridin-2-yloxy)propoxy]benzene”

(A1N 29/10, A01N 31/14)

139577

Pesticidal composition containing as active ingredients 3,5-dichloro-1-(3,3-dichloro-2-propenyloxy)-4-[3-(5-trifluoromethylpyridin-2-yloxy)propoxy]benzene of the formula:



And at least one Carbamate compound selected from thiodicarb, methomyl and alanycarb have excellent pesticidal activity by their synergistic cooperative action,


728/1999 Novartis AG.  
Switzerland.

“A composition comprising tegaserod”

(A61K 9/14)

139578

The present invention relates to a solid oral pharmaceutical composition comprising compound A




Compound (A)

Or its salts; comprising a disintegrant which is present in an amount of at least 15% by weight based on the total weight of the composition, wherein the disintegrant is a member selected from the group consisting of crospovidone, pregelatinised starch, sodium starch glycolate, carboxymethylcellulose sodium, carboxymethylcellulose calcium sodium alginate, and a mixture thereof.

823/1999 Wyeth Holdings Corporation, USA. "Substituted-3-cyanoquinoline" (C07D 215/02) 139579

This invention provides a compound of formula 1




Where X, G1, G2, R1 and R4 are defined herein useful as antineoplastic agents.

883/1999 Boehringer Ingelheim Pharma GmbH & Co. KG. Germany. "Liquid composition with formoterol, suitable for storage" (A61K 31/165) 139580

The present invention relates to a formoterol active substance concentrate suitable for storage, in the form of a solution or suspension for use in inhalers for inhalation or nasal therapy.

12/2000 Alizyme Therapeutics Limited. United Kingdom. "2-oxy benzoxazinone" (A61K 31/536) 139581

A compound comprising formula (I):



For use in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality, e.g. in the control and inhibition of unwanted enzymes in products and processes. The compound are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compound within formula (I), and pharmaceutical compositions containing them.

In formula (I)<sub>A</sub> is a 6-membered aromatic or heteroaromatic ring; and R1 is branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.

40/2000 Kissei  
Pharmaceutical  
Co. Ltd.  
Japan.

“Crystalline polymorph of aminoethylphenoxyacetic acid.”

(C07D 213/10 A61K 31/196)

139582

A crystalline polymorph of 2-[4-[2-[[[(IS, 2R) -2-hydroxy-2-(4-hydroxyphenyl)-1-methyl-ethyl] amino] ethyl]phenoxy] acetic acid having potent

$\beta_2$ - and  $\beta_3$ - adrenoceptor stimulating effects and being useful as an agent for relieving pain and promoting the removal of calculi in urolithiasis. [Means for Solution]

A crystalline polymorph having strong diffraction peaks (diffraction angle:  $2\theta \pm 0.1^\circ$ ) at 10.8, 19.1, 19.3, 19.8, 20.6 and 27.0° in powder X-ray diffraction pattern. The crystalline polymorph can be prepared by hydrolyzing ethyl 2-[4-[2-[[[(IS,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]-amino]ethyl]phenoxy]acetate phosphate with sodium hydroxide, adding an aqueous phosphoric acid solution at 40 °C and over, adding a mixed solvent of water and methanol or methanol to the resulting 2-[4-[2-[[[(IS,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl] amino] ethyl]phenoxy] acetic acid, and stirring the suspension at 40°C to reflux temperature for 30 minutes to several hours.

265/2000 The Procter &  
Gamble  
Company.  
USA.

“Cyclic peptide that is MC-4 and/ or MC-3 receptor ligand”

(C07K 7/50)

139583

Disclosed are cyclic peptide that are MC-4 and/or MC-3 receptor ligands, the analogs having a structure according to Formula (I): wherein B, X, E, Z, D, G, M', W, R, Rl, Rl', Rl 1, m, n, p and q are as described in the specification. The peptide analogs are useful in treating


diseases that are mediated by the MC-4 and/or the MC-3 receptor. As such, the invention is directed to methods of treating body weight disorders, such as obesity, anorexia, and cachexia. The invention also relates to the treatment of CNS depression, behaviour-related disorders, memory-related disorders, cardiovascular function, inflammation, sepsis, septic shock, cardiogenic shock, hypovolemic shock, sexual dysfunction, erectile dysfunction, muscle atrophy, diseases associated with nerve growth and repair, and intrauterine fetal growth. Also disclosed are pharmaceutical composition comprising the peptide analogs of Formula (I).

500/2000 F. Hoffmann-La Roche AG  
Switzerland.

“Ethanesulfonyl-Piperidine Compound”  
(C07D 211/00)

139584

The invention relates to compound of the general formula



wherein

R signify hydrogen or hydroxy;

(R)<sup>2</sup> signify hydrogen or methyl; and

X signify-O- or -(CH)<sub>2</sub>-;

It has been shown that these compounds have a good affinity to the NMDA receptor and they are therefore useful in the treatment of diseases, wherein the therapeutic indications include acute forms of neurodegeneration caused, e.g., by stroke or brain trauma; chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease or ALS (amyotrophic lateral sclerosis); neurodegeneration associated with bacterial or viral infections, and, diseases such as schizophrenia, anxiety, depression and chronic/acute pain.

981/2000 Merck Patent  
GmbH  
Germany

“N-(4, 5-Bis-Methanesulfonyl-2-Methylbenzoyl)  
guanidine hydrochloride”  
(C07C 315/00, C07C 317/00)

139585

The present invention relates to an NHE-1-selective Na<sup>+</sup>/H<sup>+</sup>-antiporter inhibitor, N-(4, 5-bis-methanesulfonyl-2-methylbenzoyl) guanidine hydrochloride, to its hydrochloride hydrate.

982/2000 Janssen  
Pharmaceutica  
N. V.  
Belgium

“Galantamine oral solution”  
(A61K 9/08, A61K 31/55)

139586


The present invention concerns an oral solution comprising galantamine or a pharmaceutical acceptable addition salt thereof;

283/2001 Wyeth,  
USA.

“A 3-cyano (AZA) quinolone “  
(C07D 215/54, C07D 401/04)

139587

This invention provides compound of Formula (I), having the structure



where T, Z, X, A, R<sup>1</sup>, R<sup>2a</sup>, R<sup>2b</sup>, R<sup>2c</sup>, R<sup>3</sup>, R<sup>4</sup>, and n are defined herein, which are useful as antineoplastic agents and in the treatment of osteoporosis and polycystic kidney disease.

974/2001 Eli Lilly and  
Company  
USA.

“2-[4-[3-[2, 5-dihydro-1-[(4-methylphenyl) methyl]-5-oxo-1H-1, 2, 4-triazol-3-yl]phenoxy]-2-methyl-propanoic acid compound”.

(C07C 257/22, C07C 281/04)

139588

Invention relates to 2-[4-[3-[2, 5-dihydro-1-[(4-methylphenyl)-5-oxo-1H-1,2,4-triazol-3-yl]phenoxy]-2-methyl-propionic acid”.

54/2002


F. Hoffmann-  
La Roche AG.  
Switzerland.

"Imidazole compound"

(INT: CL, C07D 233/54)

139589

The invention related to compound of the general formula



Wherein

A is phenyl, pyridin-2-yl, pyridin-3-yl, or piperidin-1-yl;

R<sup>1</sup>/R<sup>2</sup> are independently from each other hydrogen, halogen, lower alkyl, cycloalkyl, lower alkenyl, trifluoromethyl, -O-trifluoromethyl, -S-trifluoromethyl, S-lower alkyl, lower alkoxy, -CHF<sub>2</sub>, -C(lower alkyl)F<sub>2</sub>, -OCHF<sub>2</sub>, phenyl, nitro, benzyloxy, hydroxy or amino or are together with the carbon atoms to which they are attached in any adjacent positions -CH=CH-CH=CH-, -CH=CH-CH=N-, -(CH<sub>2</sub>)<sub>3</sub>-, -O-CH<sub>2</sub>-O-, -O-CF<sub>2</sub>-O-, -CH<sub>2</sub>-O-CH<sub>2</sub>- or -CH<sub>2</sub>CH<sub>2</sub>-O-;

R<sup>3</sup> is hydrogen, lower alkyl, cycloalkyl, phenyl, S-lower alkyl, amino, lower alkyl-amino, -NHC(O)-lower alkyl or hydroxy-lower alkyl;

R<sup>4</sup>/R<sup>5</sup> are independently from each other hydrogen or lower alkyl or are together with the carbon atom to which they are attached -(CH<sub>2</sub>)<sub>4</sub>-;

R<sup>6</sup>/R<sup>6'</sup> are independently from each other hydrogen or lower alkyl;

X is -N< or  $\begin{array}{c} | \\ -C= \end{array}$

Y is =N-, -NH-, -N=CH- or -CH=;

Z is -CR<sup>7</sup>=, -N=, -NR<sup>7</sup>-, -N=CR<sup>7</sup>-, =CH-N=C(R<sup>7</sup>)- or =N-CH=CH-;R<sup>7</sup> is hydrogen, -CH<sub>2</sub>OH or lower alkyl;

N is 0, 1 or 2;

M is 0 or 1; and

The dotted line may be a bond.

The compound is therefore suitable in the control or treatment of diseases, related to this receptor.


553/2002 Wyeth,  
USA

“Substituted naphthyl Benzofuran compound”

(A61K 31/42, C07D 257/04)

139590

This invention provides compound which act as inhibitors of plasminogen activator inhibitor-1 (PAI-1) of the formula:



Wherein: R, R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> are H, alkyl, cycloalkyl, -CH<sub>2</sub>-(cycloalkyl), alkanoyl, halo, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, perfluoroalkyl, alkoxy, amino, -NH(alkyl), -N(alkyl)<sub>2</sub>, or perfluoroalkoxy; R<sub>4</sub> is H, alkyl, perfluoroalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkenyl, alkenyl-aryl, aryl, -CH<sub>2</sub>R<sub>5</sub>, -CH(OH)R<sub>5</sub>, -C(O)R<sub>5</sub>, -CH(SH)R<sub>5</sub>, or -C(S)R<sub>5</sub>; R<sub>5</sub> is H, alkyl, perfluoroalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkenyl, alkenyl-aryl; R<sub>6</sub> is H, alkyl, cycloalkyl, -CH<sub>2</sub>-cycloalkyl, alkylaryl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl; n is an integer of 0-6; A is COOH, or an acid mimic; or a pharmaceutically acceptable salt or ester form thereof, as well as pharmaceutical compositions and methods using these compounds to treat or prevent conditions resulting from fibrinolytic disorders such as deep vein thrombosis and coronary heart disease, and pulmonary fibrosis.


718/2002 Janssen  
Pharmaceutica  
N.V.  
Belgium.

“2,4,5-trisubstituted thiazolyl compound”

(A61K 31/426 A61K 31/427 C07D 417/04)

139591

This invention concerns a compound of formula (I)  
Formual:




a N-oxide, a quaternary amine and a stereochemically isomeric form thereof, wherein Z is halo; C<sub>1-6</sub>alkyl; C<sub>1-6</sub>alkyl substituted with hydroxy, carboxyl, cyano, amino, mono -or di (C<sub>1-6</sub>alkyl)amino, aminocarbonyl, mono -or di C<sub>1-6</sub>alkylaminocarbonyl, C<sub>1-6</sub>alkyl alkyloxycarbonyl or C<sub>1-6</sub>alkyloxy; polyhaloC C<sub>1-4</sub>alkyl; C C<sub>1-4</sub>alkyloxy; cyano; amino; aminocarbonyl; mono -or di(C<sub>1-6</sub>alkyl)aminocarbonyl; C<sub>1-6</sub>alkyloxycarbonyl; C<sub>1-6</sub>alkylcarbonyloxy; H<sub>2</sub>N-S(=O)<sub>2</sub>-; mono -or di(C<sub>1-6</sub>alkyl)amino-S(=O)<sub>2</sub>; -C(=N-R<sup>x</sup>)NR<sup>y</sup>R<sup>z</sup>; Q is an optionally substituted carbocycle or an optionally substituted heterocycle; L is substituted phenyl or an optionally substituted monocyclic 5 or 6-membered partially saturated or aromatic heterocycle or a bicyclic partially saturated or aromatic heterocycle; aryl is optionally substituted phenyl; for the prevention or the treatment of diseases mediated through TNF- $\alpha$  and/or IL-12.

935/2002 Merck Patent GmbH.  
Germany.

“Hydrazono-Malonitrile”  
(C07D 237/04)

139592

Hydrazono-malonitrile of the Formula 1:




in which R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>3'</sup> and R<sup>4</sup> have the meanings given in Claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.

975/2002 F. Hoffmann-La Roche AG.  
Switzerland.

“Nicotin benzothiazole compound.”  
(INT: CL, C07D 413/14)

139593

The present invention relates to compound of the general formula



wherein

R<sup>1</sup> is phenyl, piperidin-1-yl or morpholinyl;

A is -O- and

R is -(CH<sub>2</sub>)<sub>n</sub>-N(R'')-C(O)-lower alkyl, -(CH<sub>2</sub>)<sub>n</sub>-O-lower alkyl, -(CH<sub>2</sub>)<sub>n</sub>-O-(CH<sub>2</sub>)<sub>n</sub>-O-lower alkyl, lower alkyl, -(CH<sub>2</sub>)<sub>n</sub>-morpholinyl,

-(CH<sub>2</sub>)<sub>n</sub>-phenyl, -(CH<sub>2</sub>)<sub>n</sub>-N(R'')<sub>2</sub>, -(CH<sub>2</sub>)<sub>n</sub>-pyridinyl, -(CH<sub>2</sub>)<sub>n</sub>-(CF)<sub>3</sub>, -(CH<sub>2</sub>)<sub>n</sub>-2-oxo-pyrrolidinyl or (C<sub>4-6</sub>-cycloalkyl); R'' is independently from each other hydrogen or lower alkyl and n is 1 or 2; or A is -N(R')- and R is lower alkyl, (C<sub>4-6</sub>-cycloalkyl, -(CH<sub>2</sub>)<sub>n</sub>-O-lower alkyl, -(CH<sub>2</sub>)<sub>n</sub>-pyridinyl, -(CH<sub>2</sub>)<sub>n</sub>-piperidinyl, -(CH<sub>2</sub>)<sub>n</sub>-phenyl, -(CH<sub>2</sub>)<sub>n</sub>-N(R'')-C(O)-lower alkyl,


-(CH<sub>2</sub>)<sub>n</sub>-morpholinyl, or -(CH<sub>2</sub>)<sub>n</sub>-N(R'')<sub>2</sub>; R' and R'' are independently from each other hydrogen or lower alkyl and n is 1 or 2; or A is -(CH<sub>2</sub>- and R is -N(R'')-(CH<sub>2</sub>)<sub>m</sub>-O-lower alkyl, -N(R'')<sub>2</sub>, S-lower alkyl, or is acetidinyl, pyrrolidinyl or piperidinyl, which are optionally substituted by hydroxy or lower

alkoxy or is morpholinyl, -N(R'')-(CH<sub>2</sub>)<sub>m</sub>-(C<sub>4-6</sub>-cycloalkyl, -N(R'')-(CH<sub>2</sub>)<sub>m</sub>-C(O)O-lower alkyl, -N(R'')-(CH<sub>2</sub>)<sub>m</sub>-C(O)OH, -2-oxo-pyrrolidinyl, -N(R'')-C(O)O-lower alkyl, -O(CH<sub>2</sub>)<sub>m</sub>-O-lower alkyl or alkoxy; R'' is independently from each other hydrogen or lower alkyl and m is 1, 2 or 3; A is -S- and R is lower alkyl; or A-R are together -


piperazinyl, substituted by lower alkyl, -C(O)-lower alkyl or an oxo group, or is piperidinyl, substituted by lower alkoxy or hydroxy, or is morpholinyl, substituted by lower alkyl, or is -(C)<sub>4-6</sub>-cycloalkyl, -azetidin-1-yl, optionally substituted by hydroxy or lower alkoxy, thiomorpholine-1,1-dioxo, -tetrahydropyran or 2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl; It has been found that the compound of general formula I are adenosine receptor ligands. Specifically, the compound of the present invention have a good affinity to the (A) 2A-receptor and they are therefore useful in the treatment of diseases related to this receptor.

1012/2002 Pfizer Products Inc. USA. “Controlled-release (CR) dosage form of 5,7,14-triazatetracyclo[10.3.1.1.0<sup>2,11</sup>-O<sup>4,9</sup>]-hexadeca-2(11),3,5,7,9-pentaene”  
(A61K 31/495 A61K 9/20)  
139594

The present invention is directed to controlled-release (CR) oral pharmaceutical dosage forms of 5, 8, 14-triazatetracyclo[10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]-hexadeca-2(11),3,5,7,9-pentaene, 1, and methods of using them to reduce nicotine addiction or aiding in the cessation or lessening of tobacco use while reducing nausea as an adverse effect. The present invention also relates to an immediate-release (IR) low dosage composition having a stable formulation with uniform drug distribution and potency.



59/2003 Boehringer Ingelheim International GmbH. Germany. “Novel peptide compound”  
(C07K 7/50)  
Compound of formula (I):  
139595



Wherein R<sup>1</sup> is hydroxyl or sulfonamide compound R<sup>2</sup> is t-butyl or -CH<sup>2</sup>-C(CH<sub>3</sub>)<sub>3</sub> or -CH<sub>2</sub>-cyclopentyl; R<sup>3</sup> is t-butyl or cyclohexyl and R<sup>4</sup> is cyclobutyl, cyclopentyl or cyclohexyl; or are described as useful as inhibitor of the HCV NS3 protease.

248/2003 Glaxo Group Limited United Kingdom. “A substituted quinoline compound”  
(INT: CL, C07D 215/40)  
139596

The present invention relates to novel quinolone compound having pharmacological activity, to composition containing them and to their use in the treatment of CNS and other disorders.

293/2003	Warner-Lambert Company LLC. USA.	“Benzylsulfanyl phenoxy acetic acid compound”  (C07C 317/22)	139597
----------	----------------------------------	--	--------


### WITHDRAWN

327/2003	Chiesi Farmaceutici SPA. Italy.	“Pharmaceutical composition comprising Beclomethasone dipropionate (BDP)”  (A61K 9/10 A61K 9/72)	139598
----------	---------------------------------	--	--------

The present invention related to pharmaceutical composition in the form of sterile aqueous suspension to be administered by nebulization comprising as active ingredient a micronised corticosteroid - beclomethasone dipropionate (BDP) which produces homogenous dispersions of particles characterized by optimal size distribution is disclosed.

484/2004	Astrazeneca AB. Sweden.	“Pyrrole-2, 5-dione”  (A61P 25/28)	139599
----------	-------------------------	--	--------

The present invention relates to certain novel compound of the Formula I



Formula I

to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR)  $\alpha$  (NR1H3) and/or  $\beta$  (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to Pharmaceutical compositions containing them.

507/2004 F. Hoffmann-  
Lu Roche AG.  
Switzerland.

“A solid unit oral pharmaceutical dosage form of saquinavir mesylate”

(A61K 9/20 A61K 9/28)

139600

A solid unit oral pharmaceutical dosage form of saquinavir mesylate is provided comprising micronized saquinavir mesylate in an amount of from 250 mg to 800 mg calculated as free base, and a pharmaceutically acceptable binder, disintegrant, and water soluble carrier. A solid unit dosage form of saquinavir mesylate is provided comprising from 60% to 80% micronized saquinavir mesylate based on the mesylate salt, 4% to 8% water soluble binder, a disintegrant and a carrier, wherein each percentage is of the kernel weight.


735/2004 Warner-  
Lambert  
Company  
LLC.  
USA.

“Amino acid with affinity for the alpha-2- delta ( $\alpha$ -2- $\delta$ ) protein”

(C07C 229/08)

139601

This invention relates to certain  $\beta$ -amino acid that bind to the alpha-2-delta ( $\alpha$ 2 $\delta$ ) subunit of a calcium channel. The compound having a structure represented by formula III.



Useful in the treatment of a variety of psychiatric, pain and other disorders.


1028/2004 Bristol-Myers  
Squibb  
Company.  
USA.

“Azabicyclic heterocycle as cannabinoid receptor  
modulator”

(A61K 31/5025 C07D 487/04)

139602

The present application describes compound according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents. The compound have the general Formula I including all prodrugs, and stereoisomers, R1, R2, R3, R4, R5, m and n are described herein:




1050/2004 Pfizer Inc.  
USA.

“Triazole compound”

(C07D 401/04)

139603

Compounds of formula (I),



wherein:

X represents  $-\text{[CH}_2\text{]}_a\text{-R}$  or  $-\text{[CH}_2\text{]}_a\text{-O-[CH}_2\text{]}_b\text{-R}$ ;

a represents a number selected from 0 to 6;

b represents a number selected from 0 to 6;

R represents H,  $\text{CF}_3$  or Het; Het represents an optionally substituted 5- or 6-membered saturated, partially saturated or aromatic heterocyclic ring;

Y represents one or more substituents independently selected from  $-\text{[O]}_c\text{[CH}_2\text{]}_d\text{-(R}^1\text{)}$ , which may be the same or different at each occurrence; c at each occurrence independently represents a number selected from 0 or 1; d at each occurrence independently represents a number

selected from 0 to 6; R<sup>1</sup> at each occurrence independently represents H, halo, CF<sub>3</sub>, CN or Het<sup>1</sup>;

Het<sup>1</sup> at each occurrence independently represents a 5- or 6-membered unsaturated heterocyclic ring; V represents a direct link or -O-; Ring A represents an optionally substituted 5- to 7-membered saturated heterocyclic ring, Q represents a direct link or -N(R<sup>2</sup>)-; R<sup>2</sup> represents hydrogen or (C<sub>1-6</sub> alkyl; Z represents -[O]<sub>e</sub>-[CH<sub>2</sub>]<sub>f</sub>-(R<sup>3</sup>, a phenyl ring (optionally fused to a benzene ring or Het<sup>2</sup>, and the group as a whole being optionally substituted), or Het<sup>3</sup> (optionally fused to a

benzene ring or Het<sup>4</sup>, and the group as a whole being optionally substituted); R<sup>3</sup> represents C<sub>1-6</sub> alkyl (optionally substituted), C<sub>3-6</sub> cycloalkyl, C<sub>3-6</sub> cycloalkenyl, phenyl (optionally substituted), Het<sup>5</sup> or NR<sup>4</sup>R<sup>5</sup>; e represents a number selected from 0 or 1;

f represents a number selected from 0 to 6;

Het<sup>2</sup> and Het<sup>5</sup> independently represent optionally substituted 5- or 6-membered saturated, partially saturated or aromatic heterocyclic rings;

Het<sup>3</sup> represents an optionally substituted 4 to 6-membered saturated, partially saturated or aromatic heterocyclic ring;

Het<sup>4</sup> represents an optionally substituted 6-membered aromatic heterocyclic ring;


R<sup>4</sup> and R<sup>5</sup> independently represent optionally substituted C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkyloxy, C<sub>3-8</sub> cycloalkyl (optionally fused to C<sub>3-8</sub> cycloalkyl), Het<sup>6</sup>, or hydrogen; Het<sup>6</sup> represents an optionally substituted 5- or 6-membered saturated, partially saturated or aromatic heterocyclic ring; are useful for treating a disorder for which a V1a antagonist is indicated, in particular, dysmenorrhoea.

21/2005      Plexxikon, Inc.      "Peroxisome compound"  
USA.

(C07D 209/08)

139604

A compound having the chemical structure of formula 1, namely.



wherein:

U, V, W, X, and Y are independently CR<sup>8</sup>;

R<sup>1</sup> is -C(O)OR or a carboxylic acid isostere, wherein R is hydrogen, substituted lower alkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl; R<sup>2</sup> is -S(O)<sub>2</sub>R<sup>21</sup>; R<sup>6</sup> and R<sup>7</sup> independently hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl, or R<sup>6</sup> and R<sup>7</sup> combine to form a mono-carbocyclic or mono-heterocyclic 5- or 6-membered ring system;

R<sup>8</sup> is hydrogen, halo, optionally substituted lower alkyl, --CH<sub>2</sub>-CR<sup>12</sup> = CR<sup>13</sup>R<sup>14</sup>, optionally substituted cycloalkyl, optionally substituted monofluoroalkyl, optionally substituted difluoroalkyl, optionally substituted trifluoroalkyl, trifluoromethyl, -CH<sub>2</sub>-C=CR<sup>15</sup>, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, -OR<sup>9</sup>, ~SR<sup>9</sup>, -NR<sup>10</sup>R<sup>11</sup>, -C(Z)NR<sup>10</sup>R<sup>11</sup>-C(Z)R<sup>20</sup>, -S(O)<sub>2</sub>NR<sup>10</sup>R<sup>11</sup>, or -S(O)<sub>2</sub>NR<sup>10</sup>R<sup>11</sup>, or S-(O)<sub>2</sub>R<sup>21</sup>;

R<sup>9</sup> is optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl;


230/2005    Almirall  
 Prodesfarma,  
 S.A.  
 Spain.

“A compound comprising quinuclidine ester”

(C07D 453/02)

139605

Compound of formula (I)



Wherein the different substituents and/or radicals have the values defined in the claims. to pharmaceutical composition comprising them, as well as to combination

of said compound with other compound which are active in the treatment of respiratory. Urological or gastrointestinal disorders or diseases. Finally the invention also relates to the use of the compound of formula (I) for the treatment of respiratory urological or gastrointestinal disorders or diseases.


679/2005 Laboratorios  
Lesvi, S.L.  
Spain.

“A composition comprising solvate of olanzapine, method for preparing it, and method for preparing for I of olanzapine thereform”

(C07D 495/04 A61K 31/551)

139606

Mixed solvate of olanzapine, method for preparing it and method for preparing form I of olanzapine therefrom” Said mixed solvate is a solvate of olanzapine/water/tetrahydrofuran in the proportion 1: 1: 1/2 (I) The method for preparing said solvate comprises treating a crude anhydrous olanzapine with a mixture of tetrahydrofuran/water. The method for preparing form I of olanzapine includes desolvating the mixed solvate of formula I, by means of drying, in vacuo and under temperature-controlled conditions.



1144/2006 Glaxo Group  
Limited  
United  
Kingdom.

“A pharmaceutically acceptable salt of a quinoline compound process for its preparation and a composition comprising thereof”

(INT: CL, C17D 215/40)

139607


The present invention relates to a pharmaceutically acceptable salt of quinoline compound having pharmacological activity, to process for their preparation, to composition containing them and to their use in the treatment of CNS and other disorders.

1395/2006 Plexxikon, Inc. USA. "A pharmaceutically acceptable salt of preoxisome compound"

(07D 209/08

139608

A pharmaceutically acceptable salt of the of the general formula I as a basic addition salt with a counterion selected from the group consisting of benzathine, chlorprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium, ammonium, alkylamine, and zinc, wherein formula I has the structure.



wherein:

U, V, W, X, and Y are independently CR<sup>8</sup>;

R<sup>1</sup> is -C(O)OR or a carboxylic acid isostere, wherein R is hydrogen, substituted lower alkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl; R<sup>2</sup> is -S(O)<sub>2</sub>R<sup>21</sup>; R<sup>6</sup> and R<sup>7</sup> independently hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl, or R<sup>6</sup> and R<sup>7</sup> combine to form a mono-carbocyclic or mono-heterocyclic 5- or 6-membered ring system;

R<sup>8</sup> is hydrogen, halo, optionally substituted lower alkyl, -CH<sub>2</sub>-CR<sup>12</sup> = CR<sup>13</sup>R<sup>14</sup>, optionally substituted cycloalkyl, optionally substituted monofluoroalkyl, optionally substituted difluoroalkyl, optionally substituted trifluoroalkyl, trifluoromethyl, -CH<sub>2</sub>-C≡CR<sup>15</sup>, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, -OR<sup>9</sup>, -SR<sup>9</sup>, -NR<sup>10</sup>R<sup>11</sup>, -C(Z)NR<sup>11</sup>, -C(Z)R<sup>20</sup>, -S(O)<sub>2</sub>NR<sup>10</sup>R<sup>11</sup>, or S-(O)<sub>2</sub>R<sup>21</sup>;

R<sup>9</sup> is optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl;

BBBBBBBBBBBB

**SEALING FEES DUE**

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139317	Unilever Plc. United Kingdom	1013/2005
139318	Clariant International Limited Switzerland	139318

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Tel: 9215488